Collegium Pharmaceutical (COLL) Income from Continuing Operations (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Income from Continuing Operations of 14496000.0 for Q1 2026, up 499.75% year-over-year from 2417000.0 in Q1 2025, and down 14.54% quarter-over-quarter from 16963000.0 in Q4 2025.
Collegium Pharmaceutical (COLL) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 14496000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 499.75% year-over-year to 14496000.0; the TTM figure through Mar 2026 stood at 74949000.0 (up 70.75% YoY), while the FY2025 annual figure was 62870000.0, down 9.13% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 14496000.0, down from 16963000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 31940000.0 in Q4 2023, with the low at 17426000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 12536000.0 (2024), against an average of 9982882.35.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 183.44% in 2022, then soared 4415.1% in 2023.
- Collegium Pharmaceutical's Income from Continuing Operations stood at 7199000.0 in 2022, then surged by 543.67% to 31940000.0 in 2023, then slumped by 60.75% to 12536000.0 in 2024, then jumped by 35.31% to 16963000.0 in 2025, then dropped by 14.54% to 14496000.0 in 2026.
- Business Quant data shows COLL's Income from Continuing Operations at 14496000.0 in Q1 2026, 16963000.0 in Q4 2025, and 31507000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Collegium Pharmaceutical | 892.67 Mn | 743.35 Mn | 110.29 Mn | -15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.05 Mn |
| Mar 31, 2026 | 14.50 Mn |
| Dec 31, 2025 | 16.96 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 11.98 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 12.54 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Jun 30, 2024 | 19.61 Mn |
| Mar 31, 2024 | 27.71 Mn |
| Dec 31, 2023 | 31.94 Mn |
| Sep 30, 2023 | 20.63 Mn |
| Jun 30, 2023 | 13.01 Mn |
| Mar 31, 2023 | -17.43 Mn |
| Dec 31, 2022 | -7.20 Mn |
| Sep 30, 2022 | 457,000.00 |
| Jun 30, 2022 | -5.19 Mn |
| Mar 31, 2022 | -13.07 Mn |
| Dec 31, 2021 | -25.03 Mn |
| Sep 30, 2021 | 8.05 Mn |